CD44 and ovarian carcinoma: Novo isoflavone derivative NV-128 was found by Alvero et al. to target CD44+/MyD88+ ovarian cancer stem cells by inhibiting ATP, Cox-I and Cox-IV levels resulting in a decrease in mitochondrial function and a corresponding increase in reactive oxygen species, ultimately leading to loss of mitochondrial membrane potential and cell death.